Smoflipid® History

Smoflipid® is safe and well tolerated7-10

  • Over a 10-year history of use
  • Worldwide use in more than 6 million patients
  • Studied in more than 20 clinical trials
smoflipid history

Currently approved in the U.S.and 57 other countries, including all of the European Union and Australia


  1. Klek S, et al. Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid): a double-blind, randomised, multicentre study in adults. Clin Nutr. 2013;32(2):224-231.
  2. Wu MH, et al. Randomized clinical trial of new intravenous lipid (SMOFlipid 20%) versus medium-chain triglycerides/long-chain triglycerides in adult patients undergoing gastrointestinal surgery. JPEN J Parenter Enteral Nutr. 2014;38(7):800-808.
  3. Mertes N, et al. Safety and efficacy of a new parenteral lipid emulsion (SMOFlipid) in surgical patients: a randomized, double-blind, multicenter study. Ann Nutr Metab. 2006;50(3):253-259.
  4. Ma CJ, et al. A double-blind randomized study comparing the efficacy and safety of a composite vs a conventional intravenous fat emulsion in postsurgical gastrointestinal tumor patients. Nutr Clin Pract. 2012;27(3):410-415.